03/06/2026
🚨A commercial decision by a pharmaceutical giant. That’s what they’re calling it.
Zoladex 3.6mg, a drug used by premenopausal women with breast cancer and endometriosis to suppress ovarian function, is being pulled from the Australian PBS from November 2026. Not because it doesn’t work. Not because it’s unsafe. Because AstraZeneca decided it was commercially inconvenient.
There are currently no other PBS-listed alternatives for hormone receptor positive breast cancer patients who need ovarian suppression.
Read that again.
Women mid-treatment. Women who’ve already lost so much to this disease, their hair, their fertility, their sense of what their body is, are now being told their medication is being discontinued, and the replacement pathway isn’t confirmed yet.
A free access program has been promised. Applications are being prepared. Reviews will happen every six months.
🤯 Every six months.
Can you imagine being a woman in active treatment, waiting six months to find out if you still have access to a drug your life depends on?
This is what it looks like when women’s health is treated as an afterthought. When the system that’s supposed to protect patients can’t compel a private company to keep a critical drug listed.
We deserve better than this. We deserve certainty. We deserve a system that fights for us the way we’ve had to fight for our lives.